Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2020 · 10-Q
Revenue$10.75M$10.75M+361.3% vs Q2 2019 Net Income-$23.57M-$23.57MN/M vs Q2 2019 EPS Diluted-$0.43-$0.43N/M vs Q2 2019 Operating Income-$31,339,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$32,697,000N/M Margins · derivedOperating margin-291.6%+1238.4 pt vs Q2 2019
Net margin-219.3%+1230.7 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end